Top

Gepubliceerd in:

01-10-2004 | Artikel

Trombofilie: risicofactoren voor veneuze trombo-embolie

Auteur: Mevrouw Dr. S. Middeldorp

Gepubliceerd in: Bijblijven | Uitgave 10/2004

Samenvatting

Recent wetenschappelijk onderzoek heeft veel duidelijk gemaakt over erfelijke en verworven risicofactoren voor trombose; veel is echter ook nog niet duidelijk. Met name de praktische consequenties voor de patiënt met trombose of voor de patiënt met trombofilie vragen aandacht. In dit artikel worden de risico's op trombotische complicaties voor deze patiënten besproken en er worden aanbevelingen voor het praktisch handelen bij deze patiënten verstrekt.

vorige artikel Diepe veneuze trombose

volgende artikel Tromboflebitis: een nat verbandje of is er meer aan de hand?

Egeberg O. Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh 1965;13:516-30.PubMed

Heijboer H, Brandjes DP, Buller HR, Sturk A, Cate JW ten. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990;323:1512-6.PubMedCrossRef

Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.CrossRefPubMed

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, Ronde H de, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.CrossRefPubMed

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.PubMed

Fermo I, Vigano'D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.PubMed

Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.CrossRefPubMed

Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.PubMed

Simioni P, Prandoni P, Zanon E, Saracino MA, Scudeller A, Villalta S et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost 1996;76:187-9.PubMed

Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.CrossRefPubMed

Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.CrossRefPubMed

Middeldorp S, Henkens CMA, Koopman MMW, Pampus ECM van, Meer J van der, Hamulyak K, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20.PubMed

Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. The incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81:198-202.PubMed

Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 Suppl):401S-428S.CrossRefPubMed

Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995;92:2800-2.PubMed

Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506/Gln mutation in the gene for factor V (Factor V Leiden). N Engl J Med 1997;336:399-403.CrossRefPubMed

Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996;75:229-32.PubMed

Eichinger S, Pabinger I, Stümpflen A, Hirsch M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden. Thromb Haemost 1997;77:624-8.PubMed

Baglin C, Brown K, Luddington R, Baglin T. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: Effect of warfarin and prediction by precipitating factors. Br J Haematol 1998;100:764-8.CrossRefPubMed

Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999;81:684-9.PubMed

De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, et al. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994;72:352-8.PubMed

Belt AGM van den, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Int Med. 1997;157:2227-32.CrossRef

Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.PubMed

Meinardi JR, Middeldorp S, Kam PJ de, Koopman MMW, Pampus ECM van, Hamulyak K, et al. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect. Blood Coagul Fibrinolysis 2001;12:713-20.CrossRefPubMed

Lensen R, Bertina RMF, Vandenbroucke JPF, Rosendaal FR. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 2001;114:380-6.CrossRefPubMed

Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000;111:1223-9.CrossRefPubMed

Middeldorp S, Libourel EJ, Hamulyak K, Meer J van der, Buller HR. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001;113:553-5.CrossRefPubMed

Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: A systematic review. Circulation 2001;104:3063-8.CrossRefPubMed

Kim RJ, Becker RC. Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies. Am Heart J 2003;146:948-57.CrossRefPubMed

Bank I, Libourel EJ, Middeldorp S, Pampus ECM van, Koopman MMW, Hamulyak K, Prins MH, Meer J van der, Buller HR. Prothrombin 20210A mutation: A mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. In press 2004.

Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: Results from a large population-based study and systematic review. Thromb Haemost 2002;87:779-85.PubMed

Sanson BJ, Friederich PW, Simioni P, Zanardi S, Huisman MV, Girolami, et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996;75:387-8.PubMed

Meinardi JR, Middeldorp S, Kam PJ de, Koopman MMW, Pampus ECM van, Hamulyak K, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999;130:736-9.PubMed

Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: A meta-analysis. Lancet 2003;361:901-8.CrossRefPubMed

Middeldorp S. Low-molecular-weight heparin to prevent pre-eclampsia: There is no evidence and potential harm. Neth J Med 2004;62:69-70.PubMed

Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314:253-7.PubMed

Belt AGM van den, Prins MH, Huisman MV, Hirsh J. Familial thrombophilia: A review analysis. Clin Appl Thromb Hemost 1996;2:227-36.CrossRef

Margaglione M, D'Andrea G, Colaizzo D, Cappucci G, Popolo A del, Brancaccio V, et al. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999;82:1583-7.PubMed

Eichinger S, Weltermann A, Mannhalter C, Minar E, Bialonczyk C, Hirschl M, et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002;162:2357-60.CrossRefPubMed

Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-6.CrossRefPubMed

Palareti G, Legnani C, Cosmi B, Valdre L, Lunghi B, Bernardi F, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003;108:313-8.CrossRefPubMed

Eichinger S, Minar E, Hirschl M, Bialonczyk C, Stain M, Mannhalter C, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999;81:14-7.PubMed

De Stefano V, Martinelli I, Mannucci PM, Paciaroni K, Rossi E, Chiusolo P. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001;113:630-5.CrossRefPubMed

Miles JS, Miletich JP, Goldhaber SZ, Hennekens CH, Ridker PM. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol 2001;37:215-8.CrossRefPubMed

Kraaijenhagen RA, Anker PS in ’t, Koopman MMW, Reitsma PH, Prins MH, Buller HR. High plasma concentration of factor VIIIc: a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.PubMed

Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;343:457-62.CrossRefPubMed

Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 2004;124:504-10.CrossRef

Heijer M den, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.CrossRef

Eichinger S, Stumpflen A, Hirschl M, Bialonczyk C, Herkner K, Stain M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-9.PubMed

Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost 1996;75:859.PubMed

Rance A, Emmerich J, Fiessinger JN. Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost 1997;77:221-2.PubMed

Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998;104:332-8.CrossRefPubMed

Titel: Trombofilie: risicofactoren voor veneuze trombo-embolie
Auteur: Mevrouw Dr. S. Middeldorp
Publicatiedatum: 01-10-2004
Uitgeverij: Bohn Stafleu van Loghum
Gepubliceerd in: Bijblijven / Uitgave 10/2004
Print ISSN: 0168-9428
Elektronisch ISSN: 1876-4916
DOI: https://doi.org/10.1007/BF03059815

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Samenvatting

Log in om toegang te krijgen

Andere artikelen Uitgave 10/2004

Tromboflebitis: een nat verbandje of is er meer aan de hand?

Aneurysma aortae abdominalis

Het fenomeen van Raynaud

Perifeer arterieel vaatlijden

Diepe veneuze trombose

Redactioneel ten geleide